Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | GRM5 | P41594 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2662057 | 0.77 | NPC1 (0.51) | NPC1RAB9AGRM5SMN1; SMN2ALDH1A1 | |
| SCHEMBL2667078 | 0.77 | NPC1 (0.66) | NPC1RAB9AGRM5SMN1; SMN2ALDH1A1 | |
| SCHEMBL7905661 | 0.74 | NPC1 (0.59) | NPC1RAB9AGRM5SMN1; SMN2ALDH1A1 | |
| SCHEMBL1796312 | 0.74 | GRM5 (0.55) | NPC1RAB9AGRM5SMN1; SMN2ALDH1A1 | |
| SCHEMBL1797125 | 0.74 | GRM5 (0.49) | NPC1RAB9AGRM5SMN1; SMN2ALDH1A1 | |
| SCHEMBL12579765 | 0.74 | NPC1 (0.75) | NPC1RAB9AGRM5SMN1; SMN2ALDH1A1 | |
| SCHEMBL1795083 | 0.73 | GRM5 (0.54) | NPC1RAB9AGRM5SMN1; SMN2ALDH1A1 | |
| SCHEMBL1800369 | 0.73 | GRM5 (0.63) | NPC1RAB9AGRM5SMN1; SMN2ALDH1A1 | |
| SCHEMBL18421576 | 0.73 | NPC1 (0.65) | NPC1RAB9AGRM5SMN1; SMN2ALDH1A1 | |
| SCHEMBL2629347 | 0.73 | SMN1; SMN2 (0.64) | NPC1RAB9AGRM5SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | claimed |
| EP-2245025-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2010-11-03 | — | — | EP | claimed |
| WO-2009106209-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-09-03 | — | — | WO | claimed |
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | GLS, GCKR, HK1 | NPC1 1995/4885RAB9A 3310/4885GRM5 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.